Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports specific share transaction details:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £13.9390 per share.
- Transaction Volume: 29 shares (Mr. D. Redfern) and 25 shares (Ms. V. Whyte).
- Transaction Date: January 15, 2021.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations. It discloses two separate acquisitions of ordinary shares by executives. These transactions were not open market purchases but resulted from the re-investment of dividends paid to shareholders on January 14, 2021, on shares held within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Verify the dividend payment date of January 14, 2021, to confirm the timing of the reinvestment.
- Confirm the share price of £13.9390 against the London Stock Exchange closing price for January 15, 2021.
- Note that the transactions involved minimal volumes (29 and 25 shares) and were automatic dividend reinvestments rather than discretionary trading.